Absci

Our HEADLINE™ Phase 1/2a clinical trial continues to progress in Australia under the guidance of renowned KOLs. Rodney Sinclair and Anthony Rossi MD, FAAD, FACMS break down the clinical trial program for ABS-201, an anti-PRLR antibody engineered using AI to tackle androgenetic alopecia (male/female pattern hair loss). ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in in vivo studies. Recent translational human ex vivo scalp models demonstrated that ABS-201 effectively stimulates hair growth by regenerating the stem cell niche as well as promoting additional key growth modulators. We look forward to sharing interim data from our HEADLINE™ trial in the H2 2026. Learn more about the HEADLINE Trial: https://headlinetrial.com/

I am so proud that our work describing how we developed and experimentally validated Origin-1, our AI platform for de novo antibody design, was accepted for an oral presentation at ICLR's 2026 GEM Workshop! If you'll be in Rio please visit my dazzling teammates Simon L., Jonathan King, and Paulina Kulytė, who would so delight in opportunities to tell you more about Absci and our work. Congratulations to the entire Absci team! 

We'll be sharing our latest breakthrough in antibody discovery with the AI community at the 14th International Conference on Learning Representations (#ICLR). At the Generative and Experimental Perspectives for Biomolecular Design (#GEM) workshop, AI team members Jonathan King, Paulina Kulytė, and Simon L. will give oral and poster presentations showcasing ORIGIN-1, our next-generation AI platform for de novo antibody design. ----------- Revealed this year, ORIGIN-1 generates antibodies with atomic accuracy against "zero-prior" epitopes—target sites that lack structural data from reported antibody-antigen or protein-protein complexes involving relevant targets. 📍If you are attending ICLR in Brazil, join us at the GEM workshop on April 27, 2026! We can’t wait to dive into the models, share the experimental data, and collaborate on the future of generative biology. See you at Rio! Learn more: https://www.gembio.ai

Absci will be at the Society for Investigative Dermatology (#SID2026) Annual Meeting! The pre-eminent Prof. Ralf Paus MD, DSc, FRSB and the team at CUTANEON will be sharing exciting ex vivo data showing that ABS-201™ stimulates hair growth and regenerates stem cell niche to potentially reverse follicle miniaturization. Join us for their presentation: Novel Strategy to Promote Hair Follicle Growth and Stem Cell Activation in Human Male Scalp Skin: Targeting Prolactin Receptor with ABS-201. 📍Don’t miss out on the conversation in Chicago, May 13-16!

We'll be sharing our latest breakthrough in antibody discovery with the AI community at the 14th International Conference on Learning Representations (#ICLR). At the Generative and Experimental Perspectives for Biomolecular Design (#GEM) workshop, AI team members Jonathan King, Paulina Kulytė, and Simon L. will give oral and poster presentations showcasing ORIGIN-1, our next-generation AI platform for de novo antibody design. ----------- Revealed this year, ORIGIN-1 generates antibodies with atomic accuracy against "zero-prior" epitopes—target sites that lack structural data from reported antibody-antigen or protein-protein complexes involving relevant targets. 📍If you are attending ICLR in Brazil, join us at the GEM workshop on April 27, 2026! We can’t wait to dive into the models, share the experimental data, and collaborate on the future of generative biology. See you at Rio! Learn more: https://www.gembio.ai

What if we looked at disease through a different lens? 15 years ago I started Absci in a 200 sq ft basement lab in Portland. Saturday, I was on the TEDxPortland stage to share how my thinking about disease has completely changed since then. We treat the body like a broken machine. But what if it's not broken — what if it's stuck? What if it made a rational choice to prioritize defense over repair and it never switched back? Your body operates on a fixed energy budget. When chronic stress locks that budget into defense mode, the body "forgets" how to heal itself. Hair stops growing. Joints swell. Tissue degenerates. But underneath, the machinery for repair is still there. What if the body already knows how to heal itself — and we just have to give it permission? Huge thank you to the TEDxPortland team for an incredible production and a huge shoutout to my coach Cathey Armillas. Full video coming in a few months. Can't wait for you all to see it.

It started in a 400 sq. ft. basement lab and a deeply held belief that the future of health lies in merging human ingenuity with machine intelligence. Today, that belief blossomed into an industry-leading AI platform pioneering a new era of medicine. We are incredibly proud and excited to announce that our Founder and CEO, Sean McClain, will be taking the stage as a TEDxPortland Year 14 Speaker! At TEDxPortland, he will outline his vision for a world where we move beyond symptom management to engineering how lifesaving medicines find cures by design. Share this moment with us on Saturday, April 11 at TEDxPortland Year 14: https://lnkd.in/gFc2S94h

We're excited to welcome Jeanne Schreuder, MBA, SPHR, as Absci's SVP of People & Experience! Jeanne will be at the head of our people strategy, shaping a workplace culture where collaboration, inclusion, and high performance thrive. A seasoned leader in both people operations and strategy, she brings invaluable expertise from her time guiding HR across the biotech industry. Join us in giving Jeanne a warm welcome!

Heading to the Oregon Drug Discovery Symposium (#ODDS2026) at OHSU on April 8 & 9th? Discover what's next in biomedical innovation and drug discovery. Jan Iyer, PhD, Absci's Head of AI Product will be sharing more about our Origin-1 platform for therapeutic antibody discovery using generative artificial intelligence.